In diplopia (double vision), you see more than one image at the same time. This may occur in just one or both eyes. It may ...

Viridian's veligrotug shows promising results in treating TED patients, setting the stage for future growth in the ...

THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after 5 infusions of veligrotug.

The company’s chronic thyroid eye disease treatment, veligrotug, was able to reduce eye bulge by 56% compared with placebo.

Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase 3 clinical trial of veligrotug, an intravenously delivered ...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive ...

RBC Capital analyst Gregory Renza raised the firm’s price target on Viridian Therapeutics (VRDN) to $47 from $44 and keeps an Outperform rating ...